| pubmed-article:2459213 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2459213 | lifeskim:mentions | umls-concept:C0019733 | lld:lifeskim |
| pubmed-article:2459213 | lifeskim:mentions | umls-concept:C0567416 | lld:lifeskim |
| pubmed-article:2459213 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:2459213 | lifeskim:mentions | umls-concept:C0002520 | lld:lifeskim |
| pubmed-article:2459213 | lifeskim:mentions | umls-concept:C0019735 | lld:lifeskim |
| pubmed-article:2459213 | lifeskim:mentions | umls-concept:C1704675 | lld:lifeskim |
| pubmed-article:2459213 | lifeskim:mentions | umls-concept:C0205177 | lld:lifeskim |
| pubmed-article:2459213 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:2459213 | lifeskim:mentions | umls-concept:C1314939 | lld:lifeskim |
| pubmed-article:2459213 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:2459213 | pubmed:dateCreated | 1988-11-3 | lld:pubmed |
| pubmed-article:2459213 | pubmed:abstractText | A large series of HLA-A2/HLA-A3 recombinant genes were generated by using the in vivo recombination technique. These genes have each been modified in the last two-thirds of the third exon such that one or several HLA-A2-specific substitutions have been made in the HLA-A3 gene and vice versa. The recombinant genes were transfected into the murine cell line P815 and the transfectants were used as targets for a series of 20 human CTL lines or clones specific for HLA-A2 or HLA-A3, or restricted by HLA-A2 and specific for influenza A. Several patterns of anti-HLA-A2, anti-HLA-A3, and HLA-A2-restricted anti-influenza CTL activity were observed and when uncloned cell lines were studied, a progressive selection of some clones with a similar pattern of activity was regularly found. From the comparison of these different patterns the following conclusions can be drawn: 1) In most but not all cases both domains of the class I molecule were essential for CTL recognition, but residue 152 was critically important for the majority of CTL tested; 2) amino acids 114/116 were also critical in most cases, and their position close to amino acid 152 in the tertiary structure of the molecule may have some functional significance; and 3) amino acid 161, although highly conserved, plays an unexpected but very important role in CTL function. | lld:pubmed |
| pubmed-article:2459213 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2459213 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2459213 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2459213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2459213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2459213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2459213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2459213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2459213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2459213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2459213 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2459213 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2459213 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:2459213 | pubmed:issn | 0022-1767 | lld:pubmed |
| pubmed-article:2459213 | pubmed:author | pubmed-author:LevyJ PJP | lld:pubmed |
| pubmed-article:2459213 | pubmed:author | pubmed-author:GomardEE | lld:pubmed |
| pubmed-article:2459213 | pubmed:author | pubmed-author:SireJJ | lld:pubmed |
| pubmed-article:2459213 | pubmed:author | pubmed-author:JordanBB | lld:pubmed |
| pubmed-article:2459213 | pubmed:author | pubmed-author:YsselHH | lld:pubmed |
| pubmed-article:2459213 | pubmed:author | pubmed-author:HealyFF | lld:pubmed |
| pubmed-article:2459213 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2459213 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:2459213 | pubmed:volume | 141 | lld:pubmed |
| pubmed-article:2459213 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2459213 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2459213 | pubmed:pagination | 2487-96 | lld:pubmed |
| pubmed-article:2459213 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:meshHeading | pubmed-meshheading:2459213-... | lld:pubmed |
| pubmed-article:2459213 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:2459213 | pubmed:articleTitle | A study of functionally active amino acids involved in the interaction of HLA-A2 or HLA-A3 molecules with cytolytic T lymphocytes. | lld:pubmed |
| pubmed-article:2459213 | pubmed:affiliation | Laboratoire d'Immunologie et de Virologie des Tumeurs, INSERM 152, Paris, France. | lld:pubmed |
| pubmed-article:2459213 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2459213 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2459213 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2459213 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2459213 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2459213 | lld:pubmed |
